ArticlePloS one2026
Multi-omics integration reveals tissue-specific biosynthesis of sesquiterpenoids in the medicinal plant Eupatorium lindleyanum.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEupatorium lindleyanum is a medicinal plant rich in bioactive sesquiterpenoids, yet the genetic and regulatory basis underlying their biosynthesis remains completely unexplored. In particular, the marked tissue-specific accumulation of these compounds-abundant in aerial organs but scarce in roots-lacks a molecular explanation.
resultsHere, we integrated UPLC-MS/MS-based metabolomics with RNA-Seq transcriptomics to comprehensively profile sesquiterpenoid metabolites and their associated gene expression signatures across root, stem, leaf, and flower tissues of Eupatorium lindleyanum. A total of 321 sesquiterpenoids were identified, exhibiting distinct tissue-specific accumulation patterns with highest abundance in flower, followed by leaf. Comparative analysis revealed 299 differentially accumulated sesquiterpenoid metabolites (DSMs), which were clustered into three major groups with preferential accumulation in leaf (Cluster 1), flower (Cluster 2), and root (Cluster 3). Transcriptome sequencing generated 99.43 Gb of clean data, yielding 147743 unigenes. Integration of metabolomic and transcriptomic datasets screened 20 structural genes (88 unigenes) involved in sesquiterpenoid biosynthesis, including MVA pathway genes (ACAT, HMGCS, HMGCR, MVK, PMK, MVD), MEP pathway genes (dxs, dxr, ispD, ispE, ispF, ispG, ispH), and downstream modification genes (FDPS, IDI, GAS, GDS, NES1, GAO, FLDH). Weighted gene co-expression network analysis (WGCNA) further prioritized hub genes within modules significantly correlated with key sesquiterpenoids. Additionally, five transcription factor families (AP2/ERF, NAC, WRKY, MYB, and bHLH) were identified as potential regulators based on strong correlations with DSMs accumulation.
conclusionsThis study provides the first comprehensive view of tissue-specific sesquiterpenoid biosynthesis in Eupatorium lindleyanum, establishing a prioritized set of candidate genes and regulators for functional validation. Our findings offer a foundational resource for metabolic engineering and molecular breeding aimed at enhancing the production of pharmacologically active sesquiterpenoids in this medicinal species.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.